While current guidelines widely recommend GLP-1 receptor agonists for the treatment of CKM conditions, ongoing research will continue to inform the role of GLP-1 and dual GLP-1/GIP receptor agonists in diverse populations with kidney disease. This evidence concerns the gene GLP1R and kidney disorder.